ARMATA PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$16.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$16.88M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$115.35M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$16.30M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was -$11.73M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$173.80M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$52.48M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$69.05M.
- ARMATA PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$22.18M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$16.88M 10-Q · filed 2026-08-12 | -$41.20M 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | -$115.35M 10-Q · filed 2026-05-13 | |||||
| 2025-12-31 | -$173.80M 10-K · filed 2026-03-25 | |||||
| 2025-06-30 | -$16.30M 10-Q · filed 2026-08-12 | -$22.83M 10-Q · filed 2026-08-12 | ||||
| 2025-03-31 | -$11.73M 10-Q · filed 2026-05-13 | |||||
| 2024-12-31 | -$52.48M 10-K · filed 2026-03-25 | |||||
| 2024-06-30 | -$14.41M 10-Q · filed 2025-08-12 | -$26.41M 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | -$25.02M 10-Q · filed 2025-05-14 | |||||
| 2023-12-31 | -$69.05M 10-K · filed 2025-03-21 | |||||
| 2023-06-30 | -$9.58M 10-Q · filed 2024-08-13 | -$18.04M 10-Q · filed 2024-08-13 | -$20.91M 10-Q · filed 2023-08-14 | |||
| 2022-06-30 | -$9.21M 10-Q · filed 2023-08-14 | -$17.99M 10-Q · filed 2023-08-14 | ||||
| 2020-12-31 | -$22.18M 10-K · filed 2021-03-18 | |||||
| 2019-12-31 | -$20.42M 10-K · filed 2021-03-18 | |||||
| 2018-12-31 | -$16.70M 10-K · filed 2020-03-19 | -$12.16M 10-K · filed 2019-03-25 | ||||
| 2017-12-31 | -$2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | -$3.11M derived: sum of 2 quarters · filed 2019-03-25 | -$11.15M derived: sum of 3 quarters · filed 2019-03-25 | -$14.36M 10-K · filed 2019-03-25 | ||
| 2017-09-30 | -$779.00K 10-Q · filed 2017-11-14 | -$8.82M derived: sum of 2 quarters · filed 2017-11-14 | -$12.03M 10-Q · filed 2017-11-14 | |||
| 2017-06-30 | -$8.04M 10-Q · filed 2017-08-14 | -$11.29M 10-Q · filed 2017-08-14 | ||||
| 2016-12-31 | -$8.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$12.54M derived: sum of 2 quarters · filed 2018-03-14 | -$18.89M derived: sum of 3 quarters · filed 2018-03-14 | -$24.28M 10-K · filed 2018-03-14 | ||
| 2016-09-30 | -$3.59M 10-Q · filed 2017-11-14 | -$9.94M derived: sum of 2 quarters · filed 2017-11-14 | -$15.32M 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | -$6.35M 10-Q · filed 2017-08-14 | -$11.19M 10-Q · filed 2017-08-14 | ||||
| 2015-12-31 | -$3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$4.90M derived: sum of 2 quarters · filed 2016-11-10 | -$7.39M derived: sum of 3 quarters · filed 2016-11-10 | -$10.79M 10-K · filed 2016-03-30 | ||
| 2015-09-30 | -$1.72M 10-Q · filed 2016-11-10 | -$4.21M derived: sum of 2 quarters · filed 2016-11-10 | -$7.61M 10-Q · filed 2016-11-10 | |||
| 2015-06-30 | -$2.48M 10-K · filed 2016-03-30 | |||||
| 2014-12-31 | -$2.21M derived: 10-K 12 month − 10-K 9 month · filed 2016-03-30 | -$7.17M derived: sum of 2 quarters · filed 2016-03-30 | -$10.92M derived: sum of 3 quarters · filed 2016-03-30 | -$13.72M 10-K · filed 2016-03-30 | ||
| 2014-09-30 | -$4.97M 10-K · filed 2016-03-30 | -$8.71M derived: sum of 2 quarters · filed 2016-03-30 | -$11.51M 10-K · filed 2016-03-30 | |||
| 2014-06-30 | -$3.74M 10-K · filed 2016-03-30 | -$6.28M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |